Company profile: Avenue Therapeutics
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products via acquisition/in-licensing, development and commercialization, including IV Tramadol for post-operative pain with reduced abuse potential through a dual mechanism, AJ201 for spinal and bulbar muscular atrophy, and BAER-101 for epilepsy and acute anxiety acting as a positive allosteric modulator of alpha-2,3 subunit-containing GABAA receptors to minimize benzodiazepine-related adverse effects.
Products and services
- AJ201: A clinical-stage treatment in development for spinal and bulbar muscular atrophy, architects disease modification via multiple mechanisms including degradation of mutant androgen receptor protein
- BAER-101: A receptor-selective therapy in development for epilepsy and acute anxiety, acts as a positive allosteric modulator of α2,3 subunit‑containing GABAA receptors to minimize benzodiazepine-associated adverse effects
- IV Tramadol: A dual-mechanism, intravenous therapy in development for managing post‑operative pain, designed to block pain signals with reduced abuse potential
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Avenue Therapeutics
IRLAB Therapeutics
HQ: Sweden
Website
- Description: Provider of drug discovery and development for brain disorders, targeting core dysfunctions in Parkinson’s disease and dementias. Offers ISP, a proprietary systems pharmacology platform built on a unique CNS compound database, and is advancing two phase II candidates: Mesdopetam (IRL790) for levodopa-induced dyskinesia and Pirepemat (IRL752) for impaired balance and reducing falls in Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IRLAB Therapeutics company profile →
Synergia Medical
HQ: Belgium
Website
- Description: Provider of optoelectronic neurostimulation devices and platforms, including NAO.VNS for drug-resistant epilepsy via Vagus Nerve Stimulation, and technologies such as non-metallic encapsulation, fast wireless charging, custom optical leads, and miniaturized photovoltaic cells to advance therapies for chronic pain, Parkinson’s disease, epilepsy, sleep apnea, and depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synergia Medical company profile →
Proximagen
HQ: United Kingdom
Website
- Description: Provider of neuroscience research and drug development targeting neurodegenerative disorders, including Parkinson's disease and Alzheimer's disease; publicly traded.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Proximagen company profile →
Penumbra
HQ: United States
Website
- Description: Provider of neurovascular and peripheral vascular devices, including: Lightning Flash mechanical thrombectomy for pulmonary embolism and venous thrombus; Penumbra System for mechanical thrombectomy in acute ischemic stroke due to intracranial large vessel occlusions; Artemis Neuro Evacuation Device for controlled aspiration; Indigo System for arterial/venous clot removal; PC400 coils for aneurysms and malformations; and POD400/PAC400 for predictable vessel occlusion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Penumbra company profile →
4P-Pharma
HQ: France
Website
- Description: Provider of clinical-stage regenerating active drugs and therapies for serious diseases, including 4P004, a GLP-1 analog for osteoarthritis; 4P022, an AI platform-based treatment for systemic sclerosis; 4P025 for primary sclerosing cholangitis; 4P021, a CXCR4 antagonist for acute respiratory distress syndrome and pulmonary complications; and 4P020, a beta-3 adrenergic receptor agonist for Stargardt disease and dry age-related macular degeneration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P-Pharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Avenue Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Avenue Therapeutics
2.2 - Growth funds investing in similar companies to Avenue Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Avenue Therapeutics
4.2 - Public trading comparable groups for Avenue Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →